Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (GB:0JDK)
LSE:0JDK
RESEARCH TOOLSreports
Iovance Biotherapeutics (0JDK) Share Price & Analysis
1 Followers
0JDK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.22 - $18.31
Previous Close$11.9
Volume15.65K
Average Volume (3M)41.75K
Market Cap
$3.31B
Enterprise Value$3.11B
Total Cash (Recent Filing)$279.87M
Total Debt (Recent Filing)$75.86M
Price to Earnings (P/E)-6.3
Beta0.44
Next Earnings
May 07, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding279,307,043
10 Day Avg. Volume80
30 Day Avg. Volume41,748
Standard Deviation0.19
R-Squared0.00203
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)9.07
Price to Sales (P/S)25703.39
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.61K
Enterprise Value/Gross Profit-324.96
Enterprise Value/Ebitda-15.57
Forecast
1Y Price Target
$26.00Price Target Upside126.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Iovance Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe clinical hold for the IOV-LUN-202 study has been lifted, and the study is allowed to proceed after implementations of additional safety and monitoring.
Market PotentialIovance's Amtagvi is anticipated to capture a significant market share in the U.S., targeting an addressable patient population of approximately 8,000.
Regulatory ApprovalFDA grants Amtagvi accelerated approval for the treatment of unresectable or metastatic melanoma.
Bears Say
Clinical Development ConcernsClinical hold for LN-145 in NSCLC after a report of a Grade 5 serious adverse event (patient death).
Financial Health RisksIovance reports a cash burn of $320-340 million, which is projected to fund operations until the second half of 2025.
Regulatory And Safety IssuesThe label includes a boxed warning noting risk of treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.
---
Options Prices
Currently, No data available
---
Ownership Overview
12.61% Insiders
16.13% Mutual Funds
16.97% Other Institutional Investors
54.29% Public Companies and
Individual Investors
0JDK FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest share price was $3.22 and its highest was $18.31 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Currently, no data Available
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 07, 2024 which is in 10 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Feb 28, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.431 by -$0.019.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -$0.42.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 279,307,040 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.431. Following the earnings report the stock price went down -5.943%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Among the largest hedge funds holding Iovance Biotherapeutics Inc’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics Inc’s shares valued at 97M.
---
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (126.09% Upside)
$26.00 (126.09% Upside)
Blogger Sentiment
Bullish
GB:0JDK Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $48.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.43%
12-Months-Change
Fundamentals
Return on Equity
-81.91%
Trailing 12-Months
Asset Growth
17.53%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
0JDK Earnings Call
Q4 2024
0:00 / 0:00
---
0JDK Stock 12 Months Forecast
Average Price Target
$26.00
▲(126.09% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Corbus Pharmaceuticals
―
Kura Oncology
―
Moderna
―
Arcturus Therapeutics
―
Best Analysts Covering 0JDK
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+26.48%
assigned a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +26.48% per trade.
---